Unicycive Therapeutics (UNCY) Free Cash Flow (2020 - 2026)
Unicycive Therapeutics posted quarterly Free Cash Flow of -$6.2 million for Q1 2026, up 29.94% year-on-year from -$4.8 million in Q1 2025, and up 22.2% on a QoQ basis from -$8.0 million in Q4 2025.
Unicycive Therapeutics (UNCY) has 7 years of Free Cash Flow data on file, last reported at -$6.2 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 29.94% year-over-year to -$6.2 million; the trailing twelve-month figure through Mar 2026 stood at -$28.7 million (up 7.82% YoY), and the FY2025 full-year result was -$31.3 million, down 9.4% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$6.2 million, up from -$8.0 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$3.0 million in Q1 2022 and bottomed at -$9.3 million in Q3 2024.
- The 5-year median for Free Cash Flow is -$6.1 million (2022), against an average of -$5.9 million.
- The widest annual swing landed in 2022, when Free Cash Flow plunged 1304.15%; it then surged 35.71% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$6.1 million in 2022, then increased by 27.04% to -$4.4 million in 2023, then slumped by 48.01% to -$6.6 million in 2024, then slipped by 22.25% to -$8.0 million in 2025, then rose by 22.2% to -$6.2 million in 2026.
- The last three Free Cash Flow figures came in at -$6.2 million (Q1 2026), -$8.0 million (Q4 2025), and -$6.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - | -6.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.25 Mn |
| Mar 31, 2026 | -6.25 Mn |
| Dec 31, 2025 | -8.03 Mn |
| Dec 31, 2025 | -8.03 Mn |
| Sep 30, 2025 | -5.96 Mn |
| Sep 30, 2025 | -5.96 Mn |
| Jun 30, 2025 | -8.43 Mn |
| Jun 30, 2025 | -8.43 Mn |
| Mar 31, 2025 | -8.92 Mn |
| Mar 31, 2025 | -8.92 Mn |
| Dec 31, 2024 | -6.57 Mn |
| Dec 31, 2024 | -6.57 Mn |
| Sep 30, 2024 | -9.28 Mn |
| Sep 30, 2024 | -9.28 Mn |
| Jun 30, 2024 | -6.34 Mn |
| Jun 30, 2024 | -6.34 Mn |
| Mar 31, 2024 | -6.46 Mn |
| Mar 31, 2024 | -6.46 Mn |
| Dec 31, 2023 | -4.44 Mn |
| Dec 31, 2023 | -4.44 Mn |
| Sep 30, 2023 | -4.42 Mn |
| Sep 30, 2023 | -4.42 Mn |
| Jun 30, 2023 | -5.50 Mn |
| Jun 30, 2023 | -5.50 Mn |
| Mar 31, 2023 | -3.92 Mn |
| Mar 31, 2023 | -3.92 Mn |
| Dec 31, 2022 | -6.08 Mn |
| Dec 31, 2022 | -6.08 Mn |
| Sep 30, 2022 | -3.56 Mn |
| Sep 30, 2022 | -3.56 Mn |
| Jun 30, 2022 | -3.05 Mn |
| Jun 30, 2022 | -3.05 Mn |
| Mar 31, 2022 | -2.96 Mn |
| Mar 31, 2022 | -2.96 Mn |
| Dec 31, 2021 | -1.40 Mn |
| Dec 31, 2021 | -1.40 Mn |
| Sep 30, 2021 | -3.47 Mn |
| Sep 30, 2021 | -3.47 Mn |
| Jun 30, 2021 | -217,000.00 |
| Jun 30, 2021 | -217,000.00 |
| Mar 31, 2021 | -673,000.00 |
| Mar 31, 2021 | -673,000.00 |
| Dec 31, 2020 | -538,000.00 |
| Dec 31, 2020 | -538,000.00 |
| Sep 30, 2020 | -706,000.00 |
| Sep 30, 2020 | -706,000.00 |